Protein Kinase C
Menée sur des lignées cellulaires et à l'aide de xénogreffes, cette étude met en évidence des mécanismes par lesquels l'inhibition de la protéine kinase
The epithelial-mesenchymal transition program becomes activated during malignant progression and can enrich for cancer stem cells (CSCs). We report that inhibition of protein kinase C
α (PKCα) specifically targets CSCs but has little effect on non-CSCs. The formation of CSCs from non-stem cells involves a shift from EGFR to PDGFR signaling and results in the PKCα-dependent activation of FRA1. We identified an AP-1 molecular switch in which c-FOS and FRA1 are preferentially utilized in non-CSCs and CSCs, respectively. PKCα and FRA1 expression is associated with the aggressive triple-negative breast cancers, and the depletion of FRA1 results in a mesenchymal-epithelial transition. Hence, identifying molecular features that shift between cell states can be exploited to target signaling components critical to CSCs.
"Inhibition of PKC
α preferentially targets breast cancer stem cells
"
Activation of an EMT program induces a shift from EGFR to PDGFR signaling
"
Activation of an AP-1 molecular switch involves c-FOS and FRA1 in CSCs
"
FRA1 is required for the EMT phenotype and tumor-initiation ability